moatshark My

All holdings

Roivant Sciences

ROIV

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
2
In their latest 13F (Q3 2026)
See who
Value held
$76.5m
Combined value at quarter end
Last quarter
1 bought
0 sold or trimmed
Price at Q2 ’26 end
$35.39
+27.8% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

+9.2%Q3 ’24
+2.5%Q4 ’24
-14.7%Q1 ’25
+11.7%Q2 ’25
+34.3%Q3 ’25
+43.4%Q4 ’25
+27.6%Q1 ’26
+27.8%Q2 ’26
Q3 ’24: +9.2%; Q4 ’24: +2.5%; Q1 ’25: -14.7%; Q2 ’25: +11.7%; Q3 ’25: +34.3%; Q4 ’25: +43.4%; Q1 ’26: +27.6%; Q2 ’26: +27.8%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

0Q4 ’23
1Q1 ’24
1Q2 ’24
1Q3 ’24
1Q4 ’24
1Q1 ’25
1Q2 ’25
1Q3 ’25
2Q4 ’25
1Q1 ’26
2Q2 ’26
0Q3 ’26
Q4 ’23: 0; Q1 ’24: 1; Q2 ’24: 1; Q3 ’24: 1; Q4 ’24: 1; Q1 ’25: 1; Q2 ’25: 1; Q3 ’25: 1; Q4 ’25: 2; Q1 ’26: 1; Q2 ’26: 2; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Roivant Sciences.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Roivant Sciences
Greenlight Capital1.9%$76.2m$76.2mUnchanged10 qtrs
Polen Capital Management0.0%$306k$306kNew1 qtr

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Roivant Sciences
Bought or soldFiling
1 Oct 2026Epperly Melissa B,Director▼ Sold16,850$36.08$608kForm 4
1 Oct 2026Epperly Melissa B,Director▼ Sold900$36.57$33kForm 4
30 Sep 2026Venker EricPresident & Immunovant CEO▼ Sold200,000$36.62$7.3mForm 4
15 Sep 2026Fitzgerald MeghanDirector▼ Sold4,712$39.68$187kForm 4
15 Sep 2026Epperly Melissa B,Director▼ Sold4,338$39.65$172kForm 4
15 Sep 2026Epperly Melissa B,Director▼ Sold600$40.38$24kForm 4
15 Sep 2026Fitzgerald MeghanDirector▼ Sold400$40.45$16kForm 4
8 Sep 2026Fitzgerald MeghanDirector▼ Sold20,000$39.90$798kForm 4
28 Aug 2026Venker EricPresident & Immunovant CEO▼ Sold166,182$35.63$5.9mForm 4
28 Aug 2026Venker EricPresident & Immunovant CEO▼ Sold33,818$36.44$1.2mForm 4
21 Aug 2026Sukhatme MayukhPresident & CIO▼ Sold144,756$36.48$5.3mForm 4
20 Aug 2026Sukhatme MayukhPresident & CIO▼ Sold17,519$37.30$653kForm 4
19 Aug 2026Sukhatme MayukhPresident & CIO▼ Sold172,899$37.17$6.4mForm 4
18 Aug 2026Sukhatme MayukhPresident & CIO▼ Sold105,141$36.59$3.8mForm 4
18 Aug 2026Sukhatme MayukhPresident & CIO▼ Sold31,801$37.18$1.2mForm 4
17 Aug 2026Sukhatme MayukhPresident & CIO▼ Sold284,707$36.25$10.3mForm 4
14 Aug 2026Sukhatme MayukhPresident & CIO▼ Sold243,177$36.23$8.8mForm 4
27 Jul 2026Venker EricPresident & Immunovant CEO▼ Sold200,000$34.95$7.0mForm 4

About the company

Sector
Health care · Pharmaceutical Preparations
Incorporated in
Bermuda
Financial year ends
31 March
Shares outstanding
722m at 31 Jul 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$23.8mMar ’21
$55.3mMar ’22
$31.5mMar ’23
$32.7mMar ’24
$29.1mMar ’25
$8.3mMar ’26
Mar ’21: $23.8m; Mar ’22: $55.3m; Mar ’23: $31.5m; Mar ’24: $32.7m; Mar ’25: $29.1m; Mar ’26: $8.3m
Roivant Sciences revenue and net income by year
YearRevenueNet income
Year to Mar 2026$8.3m−$300m
Year to Mar 2025$29.1m−$172m
Year to Mar 2024$32.7m$4.3bn
Year to Mar 2023$31.5m−$1.0bn
Year to Mar 2022$55.3m−$845m
Year to Mar 2021$23.8m−$809m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.